{"database":"bioimages","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Arnold Hayer"],"journal":["The Journal of Cell Biology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-JCBD-201003086"],"attach_to":["JCB"],"legend":["CV1 cells transfected with CAV1-K*R-mEGFP displayed normal cellular distribution of expressed mutant protein in the Golgi, in caveolar spots at the cell surface, and associated with endosomal structures.","(E)-(G) Treating CV1-CAV1-mEGFP cells with U18666A (5 µg/ml, 16 h) or overexpressing CAV1-mEGFP in CV1 cells (16 h) induced unassembled CAV1 in the plasma membrane and targeting of CAV1-mEGFP to Lamp1-positive late endosomes (single confocal sections).","Treatment of cells with (B) NH4Cl (20 mM, 12 h) or (C) MG132 (10 µM, 12 h) restored mEGFP fluorescence, consistent with neutralized lumenal pH and defects in ILV targeting, respectively.","In CV1 cells expressing mEGFP-mCherry (tandem-) tagged CAV1, mCherry fluorescence did not overlap with mEGFP-fluorescence in many endosomal structures indicating acid-dependent quenching of mEGFP in LE/LYS (as in Fig. 5A).","FRAP analysis of the non-caveolar surface pool of CAV1. 4 × 4 µm squares were photobleached in the periphery of either CV1-CAV1-mEGFP cells, [U18666A-treated, 5 µg/ml 16 h (n=10 cells) and untreated (n=5 cells)], or a CV1 cell line stably expressing GFP-GPI (n=15 cells).","(E, F) Cavin-1-mCherry localized to Rab5-positive EE, but not to Rab7-positive LE. Cavin-1-mCherry was coexpressed with GFP-tagged endosomal makers and CAV1-HA (not depicted) and images acquired 12 h post transfection form living cells using an epi-fluorescence setup.","CAV1-mEGFP and CAV1-mCherry colocalized in caveolar spots in the plasma membrane (acquisition adjusted in every other image to detect CAV1-mCherry in the PM), but not in many of the intracellular organelles when imaged live. (A-C), single confocal sections of live cells.","Co-overexpression of cavin-1 with CAV1 did not reverse targeting of CAV1 to intracellular vacuoles. CAV1-mCherry and cavin-1-mEGFP were cotransfected into CV1 cells and imaged live 12 h post transfection. Single confocal sections.","(A, B, C) CAV1-mCherry localized to Rab5-positive early endosomes (EE), and to Rab7 and Lamp1-positive late endosomes/lysosomes. Single confocal sections of fixed (A) or living (B, C) cells were acquired 12 h post transfection.","HeLa cells pretreated (48 h) with (D) control siRNA or (E) siRNAs targeting ESCRT components Hrs and Tsg101 (double-knockdown) were transfected with CAV1-tandem (12 h) and viewed live by confocal microscopy. The presence of yellow\" endosomes upon knockdown of Hrs and Tsg101 showed involvement of ESCRT machinery in ILV targeting of CAV1.\"","CV1-CAV1-mEGFP cells were left untreated (A) or were treated with with 5 µg/ml U18666A for 16 h (B), fixed, and viewed by confocal microscopy. U18666A treatment resulted in a non-caveolar pool of CAV1 in the plasma membrane.","Treatment of HeLa-CAV1-mRFP cells with BafA, NH4Cl or MG132 caused accumulation of CAV1-mRFP in endosomal organelles. Single confocal sections of living cells, focus set to peri-nuclear endosomes.","HeLa-CAV1-mRFP cells, treated with control siRNA (B) or siRNA targeting cavin-1 (C) were loaded with lysotracker (green, 100 nM, 1 h) and imaged live by confocal microscopy. Cavin-1 knockdown caused loss of caveolar spots in the plasma membrane and accumulation of CAV1-mRFP in acidic, lysotracker-positive organelles.","Colocalization between CAV1-mEGFP and CAV1-mCherry in endosomes was restored by treatment of cells with BafA (12 h, 0.2 µM), indicating acid-quenching of mEGFP-fluorescence. (A-C), single confocal sections of live cells.","CV1 cells expressing CAV1-mCherry were stained with lysotracker (green, 100 nM, 1 h) and imaged live to identify acidic organelles. Most acidic organelles were positive for CAV1-mCherry. (A-C), single confocal sections of live cells.","(C) Ubiquitin staining accumulated and colocalized with overexpressed CAV1-HA in Rab5-positive EE of CV1 cells. Accumulation of ubiquitin in EE was not observed in cells transfected with the lysine null mutant CAV1-K*R-HA (D), in untransfected cells (E), or in cells transfected with mRFP-Rab5/EGFP-Rab7 (F)."],"repository":["bioimages"],"figure_sub":["Image 27011 (SupFigure 1. Co-overexpression of cavin-1 with CAV1 does not rescue targeting of CAV1 to LE/LYS. - C. CAV1-mCherry, cavin-1-mEGFP.)","Image 26919 (Figure 1. Unassembled caveolin in the plasma membrane.  - F. CV1-CAV1-mEGFP. U18666A.)","Image 27012 (SupFigure 3. The lysine-null mutant CAV1-K*R.  - B. Normal cellular localization of CAV1-K*R-mEGFP)","Figure 6. CAV1 is ubiquitinated.  - E. No accumulation of ubiquitin staining in endosomes of untransfected cells.","Image 27009 (SupFigure 1. Co-overexpression of cavin-1 with CAV1 does not rescue targeting of CAV1 to LE/LYS. - C. CAV1-mCherry, cavin-1-mEGFP.)","Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.","Image 26918 (Figure 1. Unassembled caveolin in the plasma membrane.  - F. CV1-CAV1-mEGFP. U18666A.)","Image 26935 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26940 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - C. CAV1 colocalizes with Lamp1.","Image 27026 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - F. Cavin-1 does not colocalize with Rab7.)","Image 26992 (Figure 6. CAV1 is ubiquitinated.  - F. No accumulation of ubiquitin staining in endosomes of mRFP-Rab5/EGFP-Rab7 expressing cells.)","Figure 2. Cavin-1 knockdown.","Image 26915 (Figure 1. Unassembled caveolin in the plasma membrane.  - E. CV1-CAV1-mEGFP. Untreated.)","Image 26972 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - A. Limited colocalization between CAV1-mCherry and CAV1-mEGFP in endosomes.)","Image 26924 (Figure 2. Cavin-1 knockdown.  - B. HeLa-CAV1-mRFP. si-control.)","Image 27023 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - E. Cavin-1 colocalizes with Rab5.)","Image 26931 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26911 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - B. CAV1 colocalizes with Rab7.","Image 26948 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - C. CAV1 colocalizes with Lamp1.)","Image 27007 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - E. CAV1-tandem. si-Hrs+siTsg101 (HeLa).)","Image 27020 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - A. CAV1 colocalizes with Rab5.)","Image 27019 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - A. CAV1 colocalizes with Rab5.)","Image 26900 (Figure 1. Unassembled caveolin in the plasma membrane.  - A. CV1-CAV1-mEGFP. Untreated.)","Image 26925 (Figure 2. Cavin-1 knockdown.  - B. HeLa-CAV1-mRFP. si-control.)","Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - A. CAV1 colocalizes with Rab5.","Image 26909 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Image 27022 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - E. Cavin-1 colocalizes with Rab5.)","Image 26906 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Image 27002 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - D. CAV1-tandem. si-control (HeLa).)","Image 26975 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - B. CAV1-mCherry-positive endosomes are acidic.)","Image 26994 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - A. CAV1-tandem. Control.)","Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - B. CAV1-tandem. NH4Cl.","Image 27016 (Figure 1. Unassembled caveolin in the plasma membrane.  - G. CV1, CAV1-mEGFP. Overexpression.)","Image 26939 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26988 (Figure 6. CAV1 is ubiquitinated.  - E. No accumulation of ubiquitin staining in endosomes of untransfected cells. )","Image 27018 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - A. CAV1 colocalizes with Rab5.)","Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.","Image 26927 (Figure 2. Cavin-1 knockdown.  - C. HeLa-CAV1-mRFP. si-cavin-1)","Image 27000 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - C. CAV1-tandem. MG132.)","Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.","Image 27005 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - E. CAV1-tandem. si-Hrs+siTsg101 (HeLa).)","Image 26928 (Figure 2. Cavin-1 knockdown.  - C. HeLa-CAV1-mRFP. si-cavin-1)","Image 27003 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - D. CAV1-tandem. si-control (HeLa).)","Image 26914 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Image 26936 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26932 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26970 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - A. Limited colocalization between CAV1-mCherry and CAV1-mEGFP in endosomes.)","Image 26912 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Image 26902 (Figure 1. Unassembled caveolin in the plasma membrane.  - A. CV1-CAV1-mEGFP. Untreated.)","Image 27010 (SupFigure 1. Co-overexpression of cavin-1 with CAV1 does not rescue targeting of CAV1 to LE/LYS. - C. CAV1-mCherry, cavin-1-mEGFP.)","Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - B. CAV1-mCherry-positive endosomes are acidic.","Figure 1. Unassembled caveolin in the plasma membrane.  - E. CV1-CAV1-mEGFP. Untreated.","Image 26910 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Figure 1. Unassembled caveolin in the plasma membrane.  - G. CV1, CAV1-mEGFP. Overexpression.","Image 27025 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - F. Cavin-1 does not colocalize with Rab7.)","Figure 1. Unassembled caveolin in the plasma membrane.  - B. CV1-CAV1-mEGFP. U18666A.","Image 26997 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - B. CAV1-tandem. NH4Cl.)","Image 26995 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - A. CAV1-tandem. Control.)","Image 26984 (Figure 6. CAV1 is ubiquitinated.  - D. No accumulation of ubiquitin staining in Rab5-positive endosomes upon expression of the lysin-null mutant CAV1-K*R-HA.)","Image 26979 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - C. Colocalization between CAV1-mCherry and CAV1-mEGFP is restored by BafA treatment.)","Image 27015 (Figure 1. Unassembled caveolin in the plasma membrane.  - G. CV1, CAV1-mEGFP. Overexpression.)","Image 26982 (Figure 6. CAV1 is ubiquitinated.  - C. Accumulation of ubiquitin staining in Rab5-positive endosomes upon CAV1-wt-HA expression. )","Image 26990 (Figure 6. CAV1 is ubiquitinated.  - F. No accumulation of ubiquitin staining in endosomes of mRFP-Rab5/EGFP-Rab7 expressing cells.)","Image 26929 (Figure 2. Cavin-1 knockdown.  - C. HeLa-CAV1-mRFP. si-cavin-1)","Image 27014 (SupFigure 3. The lysine-null mutant CAV1-K*R.  - B. Normal cellular localization of CAV1-K*R-mEGFP)","Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - C. CAV1-tandem. MG132.","Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - F. Cavin-1 does not colocalize with Rab7.","Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes.","Image 26937 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 27006 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - E. CAV1-tandem. si-Hrs+siTsg101 (HeLa).)","SupFigure 3. The lysine-null mutant CAV1-K*R.","Image 26933 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26981 (Figure 6. CAV1 is ubiquitinated.  - C. Accumulation of ubiquitin staining in Rab5-positive endosomes upon CAV1-wt-HA expression. )","Image 26913 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Image 26977 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - B. CAV1-mCherry-positive endosomes are acidic.)","Figure 2. Cavin-1 knockdown.  - B. HeLa-CAV1-mRFP. si-control.","Image 26947 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - B. CAV1 colocalizes with Rab7.)","Image 26980 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - C. Colocalization between CAV1-mCherry and CAV1-mEGFP is restored by BafA treatment.)","SupFigure 1. Co-overexpression of cavin-1 with CAV1 does not rescue targeting of CAV1 to LE/LYS.","Image 26985 (Figure 6. CAV1 is ubiquitinated.  - D. No accumulation of ubiquitin staining in Rab5-positive endosomes upon expression of the lysin-null mutant CAV1-K*R-HA.)","Image 27001 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - C. CAV1-tandem. MG132.)","Image 26950 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - C. CAV1 colocalizes with Lamp1.)","Image 26974 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - A. Limited colocalization between CAV1-mCherry and CAV1-mEGFP in endosomes.)","Figure 1. Unassembled caveolin in the plasma membrane.  - A. CV1-CAV1-mEGFP. Untreated.","Image 26908 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - A. Limited colocalization between CAV1-mCherry and CAV1-mEGFP in endosomes.","Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - E. Cavin-1 colocalizes with Rab5.","Figure 1. Unassembled caveolin in the plasma membrane.  - F. CV1-CAV1-mEGFP. U18666A.","Image 26978 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - C. Colocalization between CAV1-mCherry and CAV1-mEGFP is restored by BafA treatment.)","Figure 6. CAV1 is ubiquitinated.","Image 27008 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - E. CAV1-tandem. si-Hrs+siTsg101 (HeLa).)","Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - E. CAV1-tandem. si-Hrs+siTsg101 (HeLa).","Image 26901 (Figure 1. Unassembled caveolin in the plasma membrane.  - A. CV1-CAV1-mEGFP. Untreated.)","Figure 6. CAV1 is ubiquitinated.  - F. No accumulation of ubiquitin staining in endosomes of mRFP-Rab5/EGFP-Rab7 expressing cells.","Image 26905 (Figure 1. Unassembled caveolin in the plasma membrane.  - B. CV1-CAV1-mEGFP. U18666A.)","Image 26907 (Figure 1. Unassembled caveolin in the plasma membrane.  - C. FRAP analysis of unassembled CAV1 in the plasma membrane.)","Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - C. Colocalization between CAV1-mCherry and CAV1-mEGFP is restored by BafA treatment.","SupFigure 3. The lysine-null mutant CAV1-K*R.  - B. Normal cellular localization of CAV1-K*R-mEGFP","Image 27021 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - E. Cavin-1 colocalizes with Rab5.)","Image 26991 (Figure 6. CAV1 is ubiquitinated.  - F. No accumulation of ubiquitin staining in endosomes of mRFP-Rab5/EGFP-Rab7 expressing cells.)","Image 27013 (SupFigure 3. The lysine-null mutant CAV1-K*R.  - B. Normal cellular localization of CAV1-K*R-mEGFP)","Image 26983 (Figure 6. CAV1 is ubiquitinated.  - C. Accumulation of ubiquitin staining in Rab5-positive endosomes upon CAV1-wt-HA expression. )","Figure 2. Cavin-1 knockdown.  - C. HeLa-CAV1-mRFP. si-cavin-1","Figure 3. CAV1 degradation requires endosomal acidification.","Image 26976 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - B. CAV1-mCherry-positive endosomes are acidic.)","Figure 1. Unassembled caveolin in the plasma membrane.","Image 26904 (Figure 1. Unassembled caveolin in the plasma membrane.  - B. CV1-CAV1-mEGFP. U18666A.)","Image 26973 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - A. Limited colocalization between CAV1-mCherry and CAV1-mEGFP in endosomes.)","Image 26986 (Figure 6. CAV1 is ubiquitinated.  - D. No accumulation of ubiquitin staining in Rab5-positive endosomes upon expression of the lysin-null mutant CAV1-K*R-HA.)","Image 26934 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26987 (Figure 6. CAV1 is ubiquitinated.  - E. No accumulation of ubiquitin staining in endosomes of untransfected cells. )","Image 26938 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26941 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26917 (Figure 1. Unassembled caveolin in the plasma membrane.  - E. CV1-CAV1-mEGFP. Untreated.)","Image 26903 (Figure 1. Unassembled caveolin in the plasma membrane.  - B. CV1-CAV1-mEGFP. U18666A.)","Image 26996 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - B. CAV1-tandem. NH4Cl.)","Image 26969 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - A. Limited colocalization between CAV1-mCherry and CAV1-mEGFP in endosomes.)","Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - D. CAV1-tandem. si-control (HeLa).","Figure 4. CAV1 and cavin-1 in the endosomal pathway.","Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - A. CAV1-tandem. Control.","Image 26930 (Figure 3. CAV1 degradation requires endosomal acidification.  - C. HeLa-CAV1-mRFP. Control and drug treatments.)","Image 26993 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - A. CAV1-tandem. Control.)","Image 26999 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - C. CAV1-tandem. MG132.)","Image 27004 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - D. CAV1-tandem. si-control (HeLa).)","Image 27024 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - F. Cavin-1 does not colocalize with Rab7.)","Image 26916 (Figure 1. Unassembled caveolin in the plasma membrane.  - E. CV1-CAV1-mEGFP. Untreated.)","Figure 6. CAV1 is ubiquitinated.  - D. No accumulation of ubiquitin staining in Rab5-positive endosomes upon expression of the lysin-null mutant CAV1-K*R-HA.","SupFigure 1. Co-overexpression of cavin-1 with CAV1 does not rescue targeting of CAV1 to LE/LYS. - C. CAV1-mCherry, cavin-1-mEGFP.","Image 27017 (Figure 1. Unassembled caveolin in the plasma membrane.  - G. CV1, CAV1-mEGFP. Overexpression.)","Image 26946 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - B. CAV1 colocalizes with Rab7.)","Figure 6. CAV1 is ubiquitinated.  - C. Accumulation of ubiquitin staining in Rab5-positive endosomes upon CAV1-wt-HA expression.","Image 26945 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - B. CAV1 colocalizes with Rab7.)","Image 26949 (Figure 4. CAV1 and cavin-1 in the endosomal pathway.  - C. CAV1 colocalizes with Lamp1.)","Image 26920 (Figure 1. Unassembled caveolin in the plasma membrane.  - F. CV1-CAV1-mEGFP. U18666A.)","Image 26998 (Figure 7. CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting.  - B. CAV1-tandem. NH4Cl.)","Image 26926 (Figure 2. Cavin-1 knockdown.  - B. HeLa-CAV1-mRFP. si-control.)","Image 26971 (Figure 5. CAV1 is exposed to the acidic lumen of late endosomes/lysosomes. - A. Limited colocalization between CAV1-mCherry and CAV1-mEGFP in endosomes.)"],"pubmed_authors":["Hemmo H. Meyer","Sabrina Engel","Danilo Ritz","Arnold Hayer","Miriam Stoeber","Ari Helenius"],"additional_accession":[]},"is_claimable":false,"name":"Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation","description":null,"dates":{"release":"2010-11-01T11:20:13Z","modification":"2018-11-29T11:20:13Z","creation":"2018-11-29T11:20:13Z"},"accession":"S-JCBD-201003086","cross_references":{"doi":["10.1083/jcb.201003086"]}}